General form of registration statement for all companies including face-amount certificate companies

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating Activities:          
Consolidated net loss $ (51,524) $ (33,405) $ (67,936) $ (38,074) $ 1,526
Adjustments to reconcile consolidated net income (loss) to cash provided by operating activities:          
Depreciation and amortization of intangibles 35,944 30,635     35,441
Deferred income taxes (563) 27 169 (1,122)
Amortization of debt discount 539 539 720 636 2,322
Amortization of deferred financing fees 566 754 900 503 137
Non-cash compensation 2,103 2,579 3,438 3,828 2,616
(Gain) loss on derivative instruments (1,565) 4,362      
Bad debt expense 27 44 45 5 306
Depreciation     40,849 38,651 35,441
Fair value adjustments     (473) 557
Inventory valuation     (350) 2,678
Change in fair value on commodity derivative instruments     6,714 2,077 1,984
Interest expense added to plant term debt     9,451
Changes in operating assets and liabilities:          
Accounts receivable (370) 12,656 12,663 17,562 (25,235)
Inventories (4,689) 6,784 4,080 5,070 750
Prepaid expenses and other assets 5,836 (2,454) (3,880) 2,677 3,189
Prepaid inventory (101) 1,839 191 6,738 (3,973)
Operating leases (7,646)      
Accounts payable and accrued expenses (6,323) 2,307 4,105 (5,538) 9,279
Net cash provided by (used in) operating activities (27,203) 26,077 1,566 36,509 37,228
Investing Activities:          
Additions to property and equipment (2,144) (10,874) (15,154) (20,866) (19,171)
Purchase of ICP, net of cash acquired     (29,574)
Proceeds from cash collateralized letters of credit     4,574
Net cash used in investing activities (2,144) (10,874) (15,154) (50,440) (14,597)
Financing Activities:          
Net proceeds from Kinergy's line of credit 22,629 9,880 7,578 (385) (11,141)
Proceeds from issuance of common stock 3,670 2,057
Proceeds from CoGen contract amendment 8,036      
Proceeds from assessment financing 728 2,043 5,618 2,096
Principal payments on borrowings (11,748) (17,500)      
Payments on capital leases (761) (772) (626) (7,089)
Preferred stock dividends paid (946) (946) (1,265) (1,265) (1,269)
Proceeds from warrant and option exercises     1,202 1,164
Payments on assessment financing     (415)
Proceeds from plant term and revolving credit agreements     42,000 97,000
Proceeds from parent notes     13,530 53,350
Payments on plant borrowings     (16,500) (59,927) (172,073)
Payments on senior notes     (2,000)
Sale of noncontrolling interests     30,000
Debt issuance costs     (986) (1,960)
Net cash provided by (used in) financing activities 21,641 (8,599) (9,274) (839) (9,922)
Net change in cash and cash equivalents (7,706) 6,604 (22,862) (14,770) 12,709
Cash and cash equivalents at beginning of period 26,627 [1] 49,489 49,489 64,259 51,550
Cash and cash equivalents at end of period 18,921 56,093 26,627 [1] 49,489 64,259
Supplemental Cash Flow Information:          
Interest paid 13,877 11,299 15,147 11,133 11,168
Income tax refunds received 743 743 5,614 4,784
Noncash financing and investing activities:          
Initial right of use assets and liabilities recorded under ASC 842 $ 43,753      
Capital leases added to plant and equipment     180
Reclass of warrant liability to equity upon exercises     178 179
Contribution of property and equipment for noncontrolling interest (see Note 2)     16,500
Debt issued in ICP acquisition (see Note 2)     $ 46,927
[1] Amounts derived from the audited consolidated financial statements for the year ended December 31, 2018.